Gastro-retentive drug delivery systems (GRDDS), in particular gastro-retentive floating drug delivery systems (GRFDDS), have become a cutting-edge method for enhancing the therapeutic efficacy and bioavailability of oral medications with limited absorption windows. These technologies allow for controlled and prolonged medication release by extending the duration of stomach residency. To accomplish successful stomach retention, a number of techniques have been developed, including multi particulate methods, raft-forming systems, and effervescent and non-effervescent floating systems. Site-specific drug administration, increased bioavailability, and better patient compliance are just a few benefits of GRFDDS, particularly for medications taken in the upper gastrointestinal tract. However, physiological elements including gastric motility, pH, and feeding circumstances, as well as formulation issues like floating lag time and drug stability, affect how well they work. medications like metformin, glimepiride, and pioglitazone, the use of GRFDDS in antidiabetic therapy has demonstrated encouraging results by increasing drug use and lowering dosage frequency. The potential of GRFDDS in efficient diabetes treatment is still being expanded by continuous developments in combination therapy techniques and formulation tactics, despite significant limitations.
S. Haripriya1*, M. Bharathi2*, V. Kannabirran2, N. Senthilkumar2, D. Rajalingam2, N. Gnanasekar2 (Mon,) studied this question.